March 16, 2018 + Jessica Di Palo
5 Min read
MTIP has invested in Nitinotes Ltd, an Israeli based company developing breakthrough, minimally invasive devices for the multi-billion dollar obesity market.
MTIP joins Elron Industries and Accelmed to expand the Series A round, bringing funds raised to $6.7M.
Nitinotes has developed the EndoZipTM, a fully automated, operator independent gastroscopic suturing system, allowing gastroenterologists as well as surgeons to bring a durable solution to their patients. The procedure creates an effect of stomach volume restriction and motility impair – both are needed to help obese patients reducing weight.
“We’ve welcomed MTIP into the round due to their experience in medical device investing and extensive networks in Europe,” said Raz Bar On, CEO of Nitinotes. “As we enter our first clinical trial, the value MTIP can bring to us in navigating the clinical and regulatory pathways will be very useful.”
“Nitinotes has a great team developing a much needed solution for the large number of obese patients that cannot lose weight from just diet and lifestyle change. said Dr Christoph Kausch Founding Partner and CEO of MTIP. “Metabolic disease including obesity are creating massive challenges for health care systems across the globe. We are excited about the potential that Nitinotes has to improve the lives of these patients.”
Bruce Meadows, the Fund’s Senior Investment Director, added that “Nitinotes is great example of the early stage companies we are looking for. The company is lean, focused on creating vale and is exceptionally managed.”
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
Oviva raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Private Equity 101: Part one – Glossary
Are you new to the healthtech space?
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper
Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch
Elite Summit 2019
MTIP Healthcare Clinic 2019
Healthcare clinic 2019
New MTIP investment in Cynerio
New investment in Cynerio
MTIP invests in Lumeon Ltd.
New investment in Lumeon
Magenverkleinerung mit der Handnähmaschine
Nitinotes news paper article
New MTIP investment in Quanta Dialysis Technologies
New investment in Quanta